Enitociclib is an experimental drug that is being investigated for the treatment of cancer.[1] It is an inhibitor of the kinase CDK9.[2][3]
Identifiers | |
---|---|
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
ChEBI | |
ChEMBL | |
Chemical and physical data | |
Formula | C19H18F2N4O2S |
Molar mass | 404.44 g·mol−1 |
3D model (JSmol) | |
| |
|
References
edit- ^ "Enitociclib - Vincerx Pharma". AdisInsight. Springer Nature Switzerland AG.
- ^ Morillo D, Vega G, Moreno V (August 2023). "CDK9 INHIBITORS: a promising combination partner in the treatment of hematological malignancies". Oncotarget. 14: 749–752. doi:10.18632/oncotarget.28473. PMC 10408673. PMID 37552223.
- ^ Frigault MM, Mithal A, Wong H, Stelte-Ludwig B, Mandava V, Huang X, et al. (November 2023). "Enitociclib, a Selective CDK9 Inhibitor, Induces Complete Regression of MYC+ Lymphoma by Downregulation of RNA Polymerase II Mediated Transcription". Cancer Research Communications. 3 (11): 2268–2279. doi:10.1158/2767-9764.CRC-23-0219. PMC 10634346. PMID 37882668.